retatrutide liver safety clinical trial retatrutide Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Triple hormone receptor agonist – Retatrutide for the treatment of – Retatrutide: A Triple Agonist Shaping

Curr Rheumatol Rep (2011) 13(2):13845

Bessette and Anderson found that 89% ( 95% CI, 87.9-90.1), 88.9% (95% CI, 87.8-90) and 90.6% (95% CI, 89.5-91.6) of the cohort met the criteria for treatment with semaglutide, liraglutide (Saxenda, Novo Nordisk) and tirzepatide (Zepbound, Eli Lilly), respectively

The dual action makes tirzepatide particularly effective at reducing appetite without relying entirely on GLP-1's side effects, while also improving lipid profiles and metabolic markers

Entrada patrocinada por CROWN Sport Nutrition

Some studies show that adding a GLP-1 agonist to basal insulin results in better blood sugar control with neutral weight effects, or even mild weight loss, compared to intensifying insulin alone

AST, aspartate aminotransferase